October 24, 2023
Collaboration agreement with Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson
The collaboration will leverage Gradient Biomodeling's expertise in quantum biomodeling and Janssen's drug development capabilities to identify and develop new antivirals for the treatment or prevention of neglected tropical diseases. In this context, Gradient Biomodeling will identify and screen for potential novel therapeutic candidates and Janssen will then take these candidates further through the discovery pipeline, including preclinical testing.Â